Fresenius Kabi Oncology Limited - Company Profile

It is a pharma public limited company based in New Delhi, Delhi, India, established in 2003.

2003 New Delhi, Delhi, India Active

Last Updated: December 30, 2025

About Fresenius Kabi Oncology Limited

Fresenius Kabi Oncology Limited, a active public limited company, was established on 18 March 2003 in New Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24231DL2003PLC119441. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹50.00 Cr and a paid-up capital of ₹48.04 Cr.

Formerly known as Dabur Pharma Limited. It upholds a compliant status. Employing 1,165 professional, Its leadership includes Nikhil Kulshreshtha (Nodal Officer), Marc Alexander Mahl (Director), Maximilian Alexander Bohmer (Director). Past directors included Dheeraj Chopra, Dilip Girdharlal Shah, Shefali Chinmoy Khaladkar. It holds no open charges and ₹240.70 Cr settled loans. Its latest AGM occurred on 20 August 2025, with the balance sheet filed on 31 March 2025. It is based at B- 310, Som Datt Chambers - I Bhikaji Cama Place, New Delhi, Delhi, 110066.

Company Details

CIN/LLPIN
U24231DL2003PLC119441
Registration Number
119441
Incorporation Date
18 March 2003
Authorized Capital
₹50.00 Cr
Paid-Up Capital
₹48.04 Cr
ROC Code
Roc Delhi
Listing Status
Unlisted
Company Status
Active

Key Metrics

Authorised Capital ₹ 50.00 Cr as on 30-12-2025
Paid Up Capital ₹ 48.04 Cr as on 30-12-2025
Company Age 22 Year, 11 Months
Last Filing with ROC 31 Mar 2025
Satisfied Charges ₹ 240.70 Cr as on 30-12-2025
Revenue Growth **** 7.09% (FY 2023)
Profit Growth **** 27.35% (FY 2023)
Ebitda **** -4.37% (FY 2023)
Net Worth 3.98% (FY 2023)
Total Assets **** 13.65% (FY 2023)

Comprehensive Company Insights

Explore comprehensive insights into Fresenius Kabi Oncology Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report

Who are the key members and board of directors at Fresenius Kabi Oncology Limited?

Current Directors

Name	Designation	Appointment Date	Status
Nikhil Kulshreshtha	Nodal Officer	19 Aug 2020	Current
Marc Alexander Mahl	Director	29 Aug 2023	Current
Maximilian Alexander Bohmer	Director	29 Aug 2023	Current
Arvind Kumar Sharma	Managing Director	01 Jul 2018	Current
Heike Susanne Van Dawen	Director	04 Jun 2024	Current
Uday Chandrashekhar Shetty	Director	25 Nov 2020	Current

Past Directors

Name	Designation	Cessation	Status
Pramod Abcsdd	Person Incharge	31 May 2012	Past
Pramod Abcsdd	Director	22 Feb 2019	Past
Pramod Abcsdd	Cfo	31 Dec 2015	Past
Pramod Abcsdd	Additional Director	29 Jul 2009	Past
Pramod Abcsdd	Whole-Time Director	19 Aug 2015	Past
Pramod Abcsdd	Additional Director	26 Aug 2024	Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Fresenius Kabi Oncology.

Fresenius Kabi Oncology Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.09% increase. The company also saw a substantial improvement in profitability, with a 27.35% increase in profit. The company's net worth moved up by a moderate rise of 3.98%.

Date	Amount	Transaction Name	Valuation	Lead Investors	Investors
Jul, 2021	Amount	Post-IPO - Grab	Valuation	investors	Emtek
Feb, 2021	Amount	Post-IPO - Grab	Valuation	investors	Signite Partners
Jan, 2021	Amount	Post-IPO - Grab	Valuation	investors	Hana Financial Group , GGV Capital
Feb, 2021	Amount	Post-IPO - Grab	Valuation	investors	Signite Partners

Upgrade Required

Full access to Financial is available only for users with an active Premium plan.

Key Matrics
Balance Sheet
Profit and Loss
Cash Flow
Ratios

Metrics

(FY 2023)

YOY Growth

(FY 2022)

(FY 2021)

(FY 2020)

(FY 2019)

Total Revenue

********

7.09%

*******

Revenue from Operations

*******

7.47%

*******

Total Assets

*******

13.65%

*******

Profit or Loss

*******

27.35%

*******

Net Worth

*******

3.98%

*******

EBITDA

*******

-4.37%

*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Fresenius Kabi Oncology?

In 2023, Fresenius Kabi Oncology had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)

Promoters: 92.83%
Public: 4.10%
Others: 3.07%

Shareholding Pattern over the Year

	FY (2024)	FY (2023)	FY (2022)	FY (2021)	FY (2020)
Promoters	92.83	94.62	94.55	94.55	94.55
Public	4.10	3.89	3.95	3.96	3.98
Others	3.07	1.49	1.50	1.49	1.47

Upgrade Required

Full access to Ownership and Shareholding Structure is available only for users with an active Premium plan.

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)

Open Charges

₹0

Satisfied Charges

₹2,407,000,000.00

Charges Breakdown by Lending Institutions

Idbi Bank Limited (Lead Bank) : 139.70 Cr
Hsbc Bank Plc : 67.00 Cr
Idbi Bank Limited : 19.00 Cr
Punjab National Bank : 15.00 Cr

Latest Charge Details

Date	Lender	Amount	Status
29 Sep 2008	Idbi Bank Limited	₹19.00 Cr	Satisfied
16 Jul 2008	Punjab National Bank	₹15.00 Cr	Satisfied
29 Sep 2006	Hsbc Bank Plc	₹67.00 Cr	Satisfied
31 Dec 2003	Idbi Bank Limited (Lead Bank)	₹139.70 Cr	Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Fresenius Kabi Oncology?

Fresenius Kabi Oncology has a workforce of 1165 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date	Number of Employees
2020	78,000
2021	80,500
2022	83,200
2023	86,000
2024	89,500
2025	92,000

Upgrade Required

Full access to People is available only for users with an active Premium plan.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Fresenius Kabi Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fresenius Kabi Oncology's trajectory.

Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Fresenius Kabi Oncology

Recent Activity within the Organization

Director Appointment

Eduardo Ricardo Dos Santos Montanha was appointed as a Additional Director was appointed as a Additional Director on 15 Sep 2025 & has been associated with this company since 5 months 10 days . was recorded as a recent event.
15 Sep 2025
Annual General Meeting

The activity Fresenius Kabi Oncology Limited last Annual general meeting of members was held on 20 Aug 2025 as per latest MCA records. was completed.
20 Aug 2025
Balance Sheet

The activity Fresenius Kabi Oncology Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi. was completed.
31 Mar 2025
Director Appointment

Heike Susanne Van Dawen was appointed as a Director was appointed as a Director on 04 Jun 2024 & has been associated with this company since 1 year 8 months . was recorded as a recent event.
04 Jun 2024
Director Appointment

Progress on Marc Alexander Mahl was appointed as a Director was appointed as a Director on 29 Aug 2023 & has been associated with this company since 2 years 5 months . was documented.
29 Aug 2023
Director Appointment

Maximilian Alexander Bohmer was appointed as a Director was appointed as a Director on 29 Aug 2023 & has been associated with this company since 2 years 5 months . was recorded as a recent event.
29 Aug 2023

Explore recent activity and updates - View Recent Activity